Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Acting Injectable Risperidone in Schizophrenia
NCT00132314Phase 3Completed
- Sponsor
- United States Department of Veterans Affairs
- Start
- Sep 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by United States Department of Veterans Affairs. Primary endpoints: Hospitalization-free Survival - Time to Event at 24 months and Hazard Ratio for Hospitalization at 24 months. Started Sep 2006; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00132314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132314.